Geovax receives notice of allowance for marburg vaccine patent

Atlanta, ga, oct. 09, 2023 (globe newswire) -- via newmediawire -- geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the u.s. patent and trademark office has issued a notice of allowance for patent application no. 17/584,231 titled “replication-deficient modified vaccinia ankara (mva) expressing marburg virus glycoprotein (gp) and matrix protein (vp40).” the allowed claims generally cover geovax's vector platform for expressing marburg virus antigens in virus-like particles (vlps) utilizing an mva viral vector.
GOVX Ratings Summary
GOVX Quant Ranking